Autophagy inhibition sensitizes hepatocellular carcinoma to the multikinase inhibitor linifanib

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Pan, Hongming ^a   Wang, Zhanggui ^a   Jiang, Liming ^a   Sui, Xinbing ^a   You, Liangkun ^a   Shou, Jiawei ^a   Jing, Zhao ^a   Xie, Jiansheng ^a   Ge, Weiting ^b   Cai, Xiujun ^a   Huang, Wendong ^c   Han, Weidong ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBANILAMIDE DERIVATIVE; INDAZOLE DERIVATIVE; N-(4-(3-AMINO-1H-INDAZOL-4-YL)PHENYL)-N1-(2-FLUORO-5-METHYLPHENYL)UREA;

ANIMAL; AUTOPHAGY; CARCINOMA, HEPATOCELLULAR; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENETICS; HEPG2 CELL LINE; HUMAN; LIVER NEOPLASMS; MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; AUTOPHAGY; CARCINOMA, HEPATOCELLULAR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; HEP G2 CELLS; HUMANS; INDAZOLES; LIVER NEOPLASMS; MICE; PHENYLUREA COMPOUNDS; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84946844556     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep06683     Document Type: Article

References (47)

1. Raza, A. & Sood, G. K. Hepatocellular carcinoma review: Current treatment, and evidence-based medicine. World journal of gastroenterology:WJG 20, 4115-4127 (2014).
2. Uhm, J. E. et al. A phase II study of oxaliplatin in combination with doxorubicin as first-line systemic chemotherapy in patients with inoperable hepatocellular carcinoma. Cancer Chemother Pharmacol 63, 929-935 (2009).
3. Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359, 378-390 (2008).
4. Albert, D. H. et al. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther 5, 995-1006 (2006).
5. Demoulin, J. B. & Essaghir, A. PDGF receptor signaling networks in normal and cancer cells. Cytokine & growth factor reviews 25, 273-283 (2014).
6. Alvarez, R. H., Kantarjian, H. M. & Cortes, J. E. Biology of platelet-derived growth factor and its involvement in disease. Mayo Clin Proc 81, 1241-1257 (2006).
7. Heldin, C. H. & Westermark, B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79, 1283-1316 (1999).
8. Ikeda, A. K. et al. ABT-869 inhibits the proliferation of Ewing Sarcoma cells and suppresses platelet-derived growth factor receptor beta and c-KIT signaling pathways. Mol Cancer Ther 9, 653-660 (2010).
9. Zhou, J. et al. Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated genes and c-Mos-mediated MAPK pathway. Leukemia 22, 138-146 (2008).
10. Toh, H. C. et al. Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma. Cancer 119, 380-387 (2013).
11. Llovet, J. M. & Hernandez-Gea, V. Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design. Clin Cancer Res 20, 2072-2079 (2014).
12. Parzych, K. R. & Klionsky, D. J. An overview of autophagy: morphology, mechanism, and regulation. Antioxidants & redox signaling 20, 460-473 (2014).
13. Xu, Y. et al. Inhibition of autophagy enhances cisplatin cytotoxicity through endoplasmic reticulum stress in human cervical cancer cells. Cancer Lett 314, 232-243 (2012).
14. Fong, M. Y. et al. Withaferin A synergizes the therapeutic effect of doxorubicin through ROS-mediated autophagy in ovarian cancer. PLoS One 7, e42265 (2012).
15. Shimizu, S. et al. Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma. Int J Cancer 131, 548-557 (2012).
16. Li, X. & Fan, Z. The epidermal growth factor receptor antibody cetuximab induces autophagyin cancer cells by downregulating HIF-1alpha and Bcl-2 and activating the beclin 1/hVps34 complex. Cancer Res 70, 5942-5952 (2010).
17. Han, W. et al. EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells. PLoS One 6, e18691 (2011).
18. Klionsky, D. J. et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 8, 445-544 (2012).
19. Rosenfeldt, M. T. & Ryan, K. M. The multiple roles of autophagy in cancer. Carcinogenesis 32, 955-963 (2011).
20. Ichimura, Y. & Komatsu, M. Selective degradation of p62 by autophagy. Semin Immunopathol 32, 431-436 (2010).
21. Frankel, L. B. et al. microRNA-101 is a potent inhibitor of autophagy. EMBO J 30, 4628-4641 (2011).
22. Farkas, T., Hoyer-Hansen, M. & Jaattela, M. Identification of novel autophagy regulators by a luciferase-based assay for the kinetics of autophagic flux. Autophagy 5, 1018-1025 (2009).
23. Ikura, Y. et al. Expression of platelet-derived growth factor and its receptor in livers of patients with chronic liver disease. J Gastroenterol 32, 496-501 (1997).
24. Maass, T. et al. Liver specific overexpression of platelet-derived growth factor-B accelerates liver cancer development in chemically induced liver carcinogenesis. Int J Cancer 128, 1259-1268 (2011).
25. Patel, S. H. et al. Clinically relevant biomarkers to select patients for targeted inhibitor therapy after resection of hepatocellular carcinoma. Ann Surg Oncol 18, 3384-3390 (2011).
26. Taylor, C. C. Platelet-derived growth factor activates porcine thecal cell phosphatidylinositol-3-kinase-Akt/PKB and ras-extracellular signal-regulated kinase-1/2 kinase signaling pathways via the platelet-derived growth factor-beta receptor. Endocrinology 141, 1545-1553 (2000).
27. Kondo, Y., Kanzawa, T., Sawaya, R. & Kondo, S. The role of autophagy in cancer development and response to therapy. Nature reviews. Cancer 5, 726-734 (2005).
28. Levy, J. M.& Thorburn, A. Targeting autophagyduring cancer therapytoimprove clinical outcomes. Pharmacol Ther 131, 130-141 (2011).
29. Bellodi, C. et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest 119, 1109-1123 (2009).
30. Gupta, A. et al. Autophagy inhibition and antimalarials promote cell death in gastrointestinal stromal tumor (GIST). Proc Natl Acad Sci U S A 107, 14333-14338 (2010).
31. Shi, Y. H. et al. Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis. Autophagy 7, 1159-1172 (2011).
32. Zhai, B. et al. Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma. Mol Cancer Ther 13, 1589-1598 (2014).
33. Ji, C. et al. Induction of autophagy contributes to crizotinib resistance in ALKpositive lung cancer. Cancer Biol Ther 15, 570-577 (2014).
34. Tavallai, S., and Hamed, H. A., Grant, S., Poklepovic, A. & Dent, P. Pazopanib and HDAC inhibitors interact to kill sarcoma cells. Cancer Biol Ther 15, 578-585 (2014).
35. Santoni, M. et al. Pazopanib and sunitinib trigger autophagic and non-autophagic death of bladder tumour cells. Br J Cancer 109, 1040-1050 (2013).
36. Ikeda, T. et al. Inhibition of autophagy enhances sunitinib-induced cytotoxicity in rat pheochromocytoma PC12 cells. J Pharmacol Sci 121, 67-73 (2013).
37. Li, X., Lu, Y., Pan, T. & Fan, Z. Roles of autophagy in cetuximab-mediated cancer therapy against EGFR. Autophagy 6, 1066-1077 (2010).
38. Zhang, T. et al. Overexpression of platelet-derived growth factor receptor alpha in endothelial cells of hepatocellular carcinoma associated with high metastatic potential. Clin Cancer Res 11, 8557-8563 (2005).
39. Chu, J. S. et al. Expression and prognostic value of VEGFR-2, PDGFR-beta, and c-Met in advanced hepatocellular carcinoma. J Exp Clin Cancer Res 32, 16 (2013).
40. Han, W. et al. Autophagy inhibition enhances daunorubicin-induced apoptosis in K562 cells. PloS one 6, e28491 (2011).
41. Wang, J. et al. A non-canonical MEK/ERK signaling pathway regulates autophagy via regulating Beclin 1. J Biol Chem 284, 21412-21424 (2009).
42. Korolchuk, V. I. et al. Lysosomal positioning coordinates cellular nutrient responses. Nat Cell Biol 13, 453-460 (2011).
43. Deter, R. L., Baudhuin, P. & De Duve, C. Participation of lysosomes in cellular autophagy induced in rat liver by glucagon. J Cell Biol 35, C11-16 (1967).
44. Zhou, J. et al. Activation of lysosomal function in the course of autophagy via mTORC1 suppression and autophagosome-lysosome fusion. Cell Res 23, 508-523 (2013).
45. Takahashi, A. et al. Autophagy guards against cisplatin-induced acute kidney injury. Am J Pathol 180, 517-525 (2012).
46. Periyasamy-Thandavan, S. et al. Autophagy is cytoprotective during cisplatin injury of renal proximal tubular cells. Kidney Int 74, 631-640 (2008).
47. Han, W. et al. Shikonin circumvents cancer drug resistance by induction of a necroptotic death. Mol Cancer Ther 6, 1641-1649 (2007).